Adam Stirling

Statistics

Publications

Citations

321

H-Index

Active since

2021

Affiliations

Radboud University Medical Center(Current)

Pfizer (United States)

Royal Marsden Hospital

Ospedale San Luigi Gonzaga

Université Paris-Saclay

Adam Stirling is an author at Radboud University Medical Center specializing in oncology, metastatic castration-resistant prostate cancer, and genitourinary cancer pharmacotherapy.

Publications per year

2021–2023

Publications

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

Johann S. de Bono, Niven Mehra, Giorgio V. Scagliotti et al. · The Lancet Oncology · 2021 · 277 citations · Full text

Medicine, Oncology, Pharmacology +16

Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses

Niven Mehra, Karim Fizazi, Johann S. de Bono et al. · The Oncologist · 2022 · 16 citations · Full text

Medicine, Oncology, Pharmacology +16

Increasing frailty is associated with higher prevalence and reduced recognition of delirium in older hospitalised inpatients: results of a multi-centre study

Waleed Faheem, Taran Nandra, Sarah Richardson et al. · European Geriatric Medicine · 2023 · 15 citations · Full text

Medicine, Geriatric Medicine, Psychiatry +17

Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1

Fred Saad, Johann S. de Bono, Philippe Barthélémy et al. · European Urology · 2022 · 13 citations · Full text

Medicine, Oncology, Pharmacology +17

1–4 of 4